fda compounded semaglutide news US proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs FDA Warns Against Using Compounded

The Drug Controller General of India seeks to safeguard public health amidst growing concerns over the wrong use of these prescription-only medications.

Furthermore, our obesogenic environment poses an insurmountable obstacle to weight loss without professional support for most PwO

Lets dig in

As your doctor, I want to walk you through how these medications work

Direct comparative validation of reta vs tirz and sema is a primary focal point in modern metabolic trials

This mini review explores the increasing prevalence of obesity in type 1 diabetes (T1D) and the challenges patients face in achieving optimal glycemic contro...